Abstract-Cardiovascular
Denopamine (TA-064) is a newly synthesized phenylethanolamine derivative (Fig. 1 ). It produced a potent positive inotropic effect without affecting systemic blood pressure (1). Although denopamine posseses a selective beta,-agonistic property, it has been shown that the increases in heart rate and myocardial oxygen consumption by denopamine are weak (1, 2). The positive inotropic effect was also observed in the experimental failing heart and after intra duodenal administration (1, 2). However, the cardiovascular effects of denopamine in conscious animals have not been shown. 
Materials and Methods
Chronically instrumented dogs: Six male mongrel dogs, weighing 10 to 16 kg, were used. The dogs were allowed to become accustomed to the laboratory and personnel. Anesthesia was induced by intravenous pentobarbital sodium (30 mg/kg), and the operation was conducted under sterile con ditions. Thoracotomy was performed at the fourth intercostal space, and an electro magnetic flow probe (Nihon Kohden) was implanted around the ascending aorta. A miniature pressure transducer (Konigsberg, P-3.5 or P-4.5) was implanted within the left ventricular chamber through an apical stab wound to provide a measurement of left ventricular pressure.
A catheter was implanted into the abdominal aorta via the left femoral artery to provide a measurement of blood pressure and sampling arterial blood. The transducer wires and the catheter were brought through the skin in the area between the scapulae. During and after the operation, antibiotics were administered.
Experiments by intravenous infusion in conscious dogs: The experiments were con ducted more than one week postoperatively when dogs had recovered from their operation. The conscious dogs were studied in the right lateral prone position. Systemic blood pressure was measured by means of a pressure transducer (Nihon Kohden, MPU 0.5) connected to an implanted catheter. Mean arterial pressure was obtained by the RC circuit (time constant, 2 sec). Left ventricular pressure was measured by con necting with the implanted pressure trans ducer via an amplifier (Nihon Kohden, AD 600G). The miniature pressure transducers were calibrated in vivo against a mercury calibrated straingauge manometer (MPU 0.5). The first derivative of the left ventricular pressure was obtained by an analogue differentiator (Nihon Kohden, EO-6000, time constant: 0.5 msec).
Heart rate was directly counted by the recording of pulse pressure for 30 or 60 sec. Aortic flow was measured by an electro magnetic flowmeter (Nihon Kohden, MF-27) as cardiac output (CO). ECG (lead II) was also monitored by attaching electrodes on the surface of the skin. Stroke volume (SV) was obtained by dividing aortic flow by heart rate, and total peripheral resistance (TPR) was calculated by dividing mean arterial pressure by aortic flow.
Denopamine at rates of 0.5, 1, 2, 4 /,cg/ kg/min was infused cumulatively for 10 min for each dose in the cannulated brachioce phalic vein. were taken intermittently at every 30 min until 3 hr and then at every 1 hr during 3 to 7 hr after dosing. At lower doses, measurements were terminated when LV dp/dtmax returned to the control level. Dogs were free and unrestrained between the measurements.
Measurements of blood levels: Blood levels of denopamine were measured in four experiments for i.v. infusion and oral adminis tration (0.4 mg/kg), respectively. In the infusion experiments a blood sample was obtained at the end of each dose and in the case of oral administration, blood samples in a volume of 10 ml were obtained at 1, 1.5, 2, 3, 5 and 7 hr after dosing. Blood levels of denopamine were measured by means of GC-MS, as described previously (3).
Drugs: Denopamine was synthesized in our Organic Chemistry Research Laboratory. Denopamine was dissolved by 0.1 N HCI and diluted with 0.9% NaCI solution.
Propranolol HCI (Inderal, Sumitomo Chem ical) was used. Statistical analysis: Results were expressed as means+S.E.M. Statistical analysis of results was performed using the paired t-test. Differences between the control and drug treatment were considered significant when P<0.05.
Results

Intravenous
infusion of denopamine to conscious dogs: Figure  2 illustrates an experimental record showing cardiovascular effects of denopamine in a conscious dog. Denopamine at a rate of 4 ,,ig/kg/min produced a marked increase in LV dp/dtmax with a concomitant increase in systolic blood pressure. Table 1 shows the summarized data of cardiovascular variables. As shown in the table, denopamine produced dose-dependent increases in LV dp,/dtmax, CO and SV. Heart rate tended to decrease at lower doses and to increase at higher doses. It also produced a nearly dose-dependent decrease in left ventricular end-diastolic pressure (LVEDP), TPR and PQ interval. Systolic blood pressure and LV systolic pressure at higher doses were increased significantly, and mean blood pressure increased slightly at higher doses.
Intravenous infusion of denopamine to anesthetized dogs: The summarized effects of denopamine in anesthetized dogs, which were the same dogs previously used in the conscious experiment, are shown in Table 2 . Pentobarbital anesthesia caused a decrease in LV dp/dtmax and a marked increase in heart rate. SV and LV systolic pressure fell, and mean aortic pressure and PQ interval tended to decrease. CO, TPR and LVEDP were not changed significantly.
Effects of denopamine upon intravenous infusion to anesthetized dogs were qualita tively similar to those in conscious dogs. Denopamine produced dose-dependent in creases in LV dp/dtmax, CO, SV, and decreases in TPR, LVEDP and PQ interval. Aortic systolic pressure and LV systolic pressure were increased at higher doses. Heart rate and respiratory frequency tended to decrease at lower doses and tended to increase at the highest dose. Denopamine produced more marked increasing effect on LV dp/dtmax (P<0.01) in terms of percent change, but less increasing effects on CO and SV in anesthetized dogs than in conscious dogs. Decreases in TPR and PQ interval were smaller in anesthetized dogs than those in conscious dogs.
Marked increase in LV dp/dtma,t upon 4 /cg/kg/min of denopamine was promptly returned to the control level by treatment with propranolol (0.2-0.5 mg/kg, i.v.), and heart rate was similarly affected (data not shown).
Oral administration of denopamine to conscious dogs: Table 3 shows the cardio vascular effects of denopamine upon oral administration in terms of peak response, and time courses are illustrated in Fig. 3 . As shown in Table 3 , denopamine produced a dose-dependent increase in LV dp/dtmax, and it caused a 66% increase at 0.4 mg/kg. Heart rate was not affected at lower doses, but it tended to increase at the highest dose. LV systolic pressure increased, while mean aortic pressure was not changed significantly. CO and SV were also increased, but an increase in SV was not dose-dependent. TPR and PQ interval were reduced. Figure 3 illustrates the time course for the effects of denopamine on LV dp/dtmax, heart rate and mean blood pressure, following oral administration.
Peak responses were obtained at 60 min after 0.1 or 0.2 mg/kg, p.o., and at 120 min after 0.4 mg/kg, p.o.
Duration of action also depended on the dosage: more than 90 min at 0.1 mg/kg, about 3 hr at 0.2 mg/kg and 7 hr at 0.4 mg/kg, respectively. Denopamine caused no significant effects on mean blood pressure and heart rate, but heart rate tended to increase during 90-120 min at 0.4 mg/kg.
Blood levels: Figure 4 illustrates relation ship between increases in LV dp/dtmax and plasma levels of denopamine.
As shown in the figure, plasma levels of denopamine pararelled the increase in LV dp/dtmax. Denopamine produced an increase in LV dp/dtma,; at plasma levels more than 5 ng/ml. Figure 3 also shows the changes in plasma levels following oral administration of denopamine at a dose of 0.4 mg/kg. Blood levels of denopamine reached the peak at 1.5-2 hr after dosing.
The positive inotropic effect and plasma levels were closely related as observed in the intravenous experiments. Fig. 3 . Time course of actions of oral denopamine on mean aortic pressure, heart rate and LV dp/dtniax in conscious dogs. Control values are shown in Table 3 . Each point represents the mean±S.E.M. creases contractile force without significant effect on blood pressure. However, the increasing effect of denopamine on heart rate was lesser than its positive inotropic action in both in vivo and in vitro experiments (1). We found these properties of deno pamine in the present experiments of chronically instrumented dogs. That is, denopamine produced a dose-dependent increase in LV dp/dtmax by both intravenous and oral administration.
It also increased CO, SV, LV systolic pressure and decreased LVEDP. These effects of denopamine reflect its positive inotropic action. The positive inotropic and chronotropic effects of denopamine were depressed by treatment with propranolol in anesthetized dogs, indicating beta-adrenoceptor-mediated responses. Inotropic selectivity has been reported in the previous paper (1) to be partly due to direct effects on the heart. This property was more remarkable in the present study in the animals with closed chest: heart rate tended to decrease at lower doses, but an increase was observed at 4 ,ug/kg/min, i.v. Since the autonomic reflex is considered more effective in conscious dogs than in open chest anesthetized dogs, this weak positive chronotropic effect may be not only due to a direct action, but also due to the baroreflex which was probably initiated by a slight increase in systolic blood pressure and an increase in rate of pressure change (4), secondary to its positive inotropic action.
Denopamine produced a marked increase in CO and a significant reduction in TPR, especially in conscious dogs, whereas weak vasodilating effects of denopamine in the femoral artery have been shown in anes thetized dogs (1). More experiments are needed to clarify the distribution of blood flow accompanied with an increase in CO. Pentobarbital is an extensively used general anesthetic for cardiovascular phar macologic studies in experimental animals. The important effects of pentobarbital on the cardiovascular system are a myocardial depressant action (5) and a marked positive chronotropic action (6, 7) due to its vagolytic effect (8-10).
In the present study, pento barbital produced a marked increase in heart rate and a decrease in LV dp/dtm,t,, while systemic blood pressure, CO and LVEDP were not affected significantly. Denopamine showed qualitatively the same cardiovascular effects in the anesthetized state as in the conscious state, but these effects were quantitatively different in some variables. In the anesthetized state, denopamine-induced increase in LV dp/dtma, was more marked in terms of percent changes. Furthermore, denopamine increased the contractility of the pentobarbital-induced failing heart in the canine heart-lung preparation (2). These findings suggest that denopamine is effective in the depressed heart as well.
In the conscious dogs, denopamine upon intravenous administration produced a positive inotropic action and the effect paralleled the blood levels of denopamine, indicating its dependence of plasma level. As shown in the relationship between blood levels of denopamine and its positive inotropic action, denopamine could produce a positive inotropic effect at more than 5 ng/ml. Kino et al. (11 ) reported that LV dp/ dtmax tended to increase at a plasma level of 15 ng/mI in patients with a diseased heart. Thus, normal conscious dogs may cause an inotropic action at a lower plasma level than in humans. The present study revealed that deno pamine was orally active and that it produced a positive inotropic action with slight effects on heart rate and blood pressure, in both conscious and anesthetized dogs.
